Therapeutic Strategies and Health Costs of Patients Admitted for a Cardiovascular Event in Italy

Abstract

Europa i soggetti di età superiore a 65 anni dovrebbero aumentare dagli 85 milioni nel 2008 ai 151 milioni nel 2060 (3). Un altro determinante di questa crescita è il miglioramento della qualità ed efficienza delle cure per le malattie CV acute, che sono in grado di aumentare la sopravvivenza dei pazienti affetti, ma che allargano la popolazione dei soggetti che necessitano di trattamenti di prevenzione secondaria (4).Nelle ultime tre decadi numerosi studi clinici hanno evidenziato l'efficacia di diversi trattamenti farmacologici capaci di ridurre l'incidenza di nuovi episodi aterotrombotici in soggetti sopravvissuti a un primo episodio; in particolare sono risultati significativamente efficaci gli antiaggreganti, i bloccanti del sistema renina-angiotensina, i beta-bloccanti, gli ipocolesterolemici. Le statine, in particolare, sono risultate un trattamento capace di ridurre la mortalità CV e i principali eventi aterotrombotici non fatali in popolazioni di pazienti eterogenee, in prevenzione sia primaria che secondaria. Questi trattamenti sono entrati a fare parte delle raccomandazioni delle linee guida sia statunitensi che europee e dovrebbero essere prescritti a tutti i pazienti che hanno già presentato

Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy

“…Our findings confirm that hospitalization is the major component of the total costs in treating patients with CVD regardless of the type of index CV event, accounting for 84.4% of total costs and 88.4% of CV-related costs in the first year after the index event. These data are consistent with other reports from Italy: a 2016 consensus study by Italian clinicians, representing all the key medical societies relevant to CVD management, showed that of the healthcare costs devoted to patients with ACS, 86.3% was spent on hospitalization [ 22 ]. This is reflected in the observation that the total number of hospital discharges in Italy for patients with ASCVD for 2017 was 439,887 [ 26 ].…”

“…We found that patients with PAD had the highest annual cost, at €14,647, followed by ACS at €14,005, while the cost for patients with IS was substantially lower at €8178. These results are complementary to a study by Lucioni et al [ 22 ] that assessed the clinical characteristics of patients in Italy in a community setting and reported on the clinical outcomes and the corresponding related costs of patients admitted for CV events. Lucioni et al reported the annual cost for patients with ACS to be €14,871, with hospitalization accounting for 86.3% of the costs, although the report indicated that only short term (1-year) follow-up was considered to evaluate costs and no LDL-C data were provided because of the lack of linkage between databases and laboratory data.…”

Cost-Effectiveness Analysis of Alirocumab in High Cardiovascular-Risk Patients in Italy

“…Even if data regarding risk of events do not derive from a national database, information used are comparable based on data found in the CORE report [21]. This document evaluates the burden of disease and healthcare costs related to about 6,000 patients treated with statins after a previous episode of acute coronary syndrome in Italy.…”